Shane R Horman
Overview
Explore the profile of Shane R Horman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
675
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Horman S, Hogan C, Delos Reyes K, Lo F, Antczak C
Future Med Chem
. 2015 Apr;
7(4):513-25.
PMID: 25875876
Increasingly, organotypic cellular platforms are being recognized as useful tools in drug discovery. This review offers an industry-centric perspective on the benefits of emerging complex cell models over conventional 2D...
12.
Velu C, Chaubey A, Phelan J, Horman S, Wunderlich M, Guzman M, et al.
J Clin Invest
. 2013 Dec;
124(1):222-36.
PMID: 24334453
Acute myelogenous leukemia (AML) subtypes that result from oncogenic activation of homeobox (HOX) transcription factors are associated with poor prognosis. The HOXA9 transcription activator and growth factor independent 1 (GFI1)...
13.
Horman S, To J, Orth A
J Biomol Screen
. 2013 Aug;
18(10):1298-308.
PMID: 23918920
There has been increasing interest in the development of cellular behavior models that take advantage of three-dimensional (3D) cell culture. To enable assessment of differential perturbagen impacts on cell growth...
14.
Horman S, Janas M, Litterst C, Wang B, MacRae I, Sever M, et al.
Mol Cell
. 2013 Apr;
50(3):356-67.
PMID: 23603119
A high-throughput RNA interference (RNAi) screen targeting 542 genes of the human kinome was used to discover regulators of RNAi. Here we report that the proto-oncogene Akt-3/PKBγ (Akt3) phosphorylates Argonaute...
15.
Khandanpour C, Phelan J, Vassen L, Schutte J, Chen R, Horman S, et al.
Cancer Cell
. 2013 Feb;
23(2):200-14.
PMID: 23410974
Most patients with acute lymphoblastic leukemia (ALL) fail current treatments highlighting the need for better therapies. Because oncogenic signaling activates a p53-dependent DNA damage response and apoptosis, leukemic cells must...
16.
Horman S, Velu C, Chaubey A, Bourdeau T, Zhu J, Paul W, et al.
Blood
. 2009 Apr;
113(22):5466-75.
PMID: 19346496
In patients with severe congenital neutropenia (SCN) and mice with growth factor independent-1 (Gfi1) loss of function, arrested myeloid progenitors accumulate, whereas terminal granulopoiesis is blocked. One might assume that...
17.
Zarebski A, Velu C, Baktula A, Bourdeau T, Horman S, Basu S, et al.
Immunity
. 2008 Mar;
28(3):370-80.
PMID: 18328744
Severe congenital neutropenia (SCN) is characterized by a deficiency of mature neutrophils, leading to recurrent bacterial and fungal infections. Although mutations in Elastase-2, neutrophil (ELA2) predominate in human SCN, mutation...
18.
Horman S, Svoboda P, Luning Prak E
J Biomed Biotechnol
. 2006 Aug;
2006(1):32713.
PMID: 16877813
The hypothesis that RNA interference constrains L1 mobility seems inherently reasonable: L1 mobility can be dangerous and L1 RNA, the presumed target of RNAi, serves as a critical retrotransposition intermediate....
19.
Farkash E, Kao G, Horman S, Luning Prak E
Nucleic Acids Res
. 2006 Mar;
34(4):1196-204.
PMID: 16507671
Long Interspersed Elements (LINE-1s, L1s) are the most active mobile elements in the human genome and account for a significant fraction of its mass. The propagation of L1 in the...